Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges-Reference-Cited by-同舟云学术

Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

Published:2023-07-24 Issue:10 Volume:20 Page:664-677
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Mountzios Giannis^ORCID,Remon Jordi,Hendriks Lizza E. L.^ORCID,García-Campelo Rosario,Rolfo Christian^ORCID,Van Schil Paul,Forde Patrick M.^ORCID,Besse Benjamin,Subbiah Vivek^ORCID,Reck Martin^ORCID,Soria Jean-Charles,Peters Solange

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://www.nature.com/articles/s41571-023-00794-7.pdf

Reference104 articles.

1. Reck, M., Remon, J. & Hellmann, M. D. First-line immunotherapy for non-small-cell lung cancer. J. Clin. Oncol. 40, 586–597 (2022).

2. Spigel, D. R. et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol. 40, 1301–1311 (2022).

3. Schmid, P. et al. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med. 382, 810–821 (2020).

4. Kelly, R. J. et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N. Engl. J. Med. 384, 1191–1203 (2021).

5. Choueiri, T. K. et al. Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma. N. Engl. J. Med. 385, 683–694 (2021).

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A computer-aided, heterodimer-based “triadic” carrier-free drug delivery platform to mitigate multidrug resistance in lung cancer and enhance efficiency;Journal of Colloid and Interface Science;2025-01

2. A multi-task deep learning model based on comprehensive feature integration and self-attention mechanism for predicting response to anti-PD1/PD-L1;International Immunopharmacology;2024-12

3. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review;International Immunopharmacology;2024-11

4. Combined targeting of senescent cells and senescent macrophages: A new idea for integrated treatment of lung cancer;Seminars in Cancer Biology;2024-11

5. Advances of immune-checkpoint inhibition of CTLA-4 in pancreatic cancer;Biomedicine & Pharmacotherapy;2024-10